Search

 
 
 
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE

If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...

SWISS TEAM STOPS BREAST CANCER METASTASIS BY FOOLING CELLS INTO BECOMING FAT

In mouse models of metastatic breast cancer, a combination of GlaxoSmithKline's diabetes drug Avandia and Novartis' cancer treatment...

 
 
 
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

BIO ROUNDUP: 2019 TRIALS, PILGRIM PRICE CHAT, PRE-XMAS SALES & MORE

It's beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather....

Pharma giant GlaxoSmithKline signs mega deal with Pfizer that could change the face of global healthcare

PHARMA GIANT GLAXOSMITHKLINE SIGNS MEGA DEAL WITH PFIZER THAT COULD CHANGE THE FACE OF GLOBAL HEALTHCARE

British pharmaceuticals giant GlaxoSmithKline will combine its consumer health business into a joint venture with US rival Pfizer to...

 
 
 
Brii Bio's Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

BRII BIO'S ALLIANCE WITH VBI VACCINES ADDS HEPATITIS B DRUG TO PIPELINE

Brii Biosciences launched earlier this year with $260 million and a mission to find new medicines in infectious disease and other therapeutic...

OncoMed's Saga Ends in Reverse Merger with UK-Based Mereo BioPharma

ONCOMED'S SAGA ENDS IN REVERSE MERGER WITH UK-BASED MEREO BIOPHARMA

OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed...

 
 
 
GSK buying cancer drugmaker Tesaro in $5.1 billion deal

GSK BUYING CANCER DRUGMAKER TESARO IN $5.1 BILLION DEAL

GlaxoSmithKline has agreed to buy US cancer drug specialist Tesaro for $5.1 billion, marking a major biotech investment by the drugmaker...

 
 
 

GLAXOSMITHKLINE'S RHEUMATOID ARTHRITIS PROSPECT MISSES PHASE 2 ENDPOINT

GlaxoSmithKline has missed the primary endpoint in a phase 2 trial of rheumatoid arthritis prospect GSK3196165. The highest dose of...

Warp Drive's Odyssey Ends with a Buyout-By Revolution, Not Sanofi

WARP DRIVE'S ODYSSEY ENDS WITH A BUYOUT-BY REVOLUTION, NOT SANOFI

Warp Drive Bio started up in 2012 with a potential buyer, Sanofi, already in place. Six years later the Cambridge, MA, company is being...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

Science ‘Mojo' and an Executive Dream Team: CEO Emma Walmsley's Bold Prescription for Reviving GlaxoSmithKline

SCIENCE ‘MOJO' AND AN EXECUTIVE DREAM TEAM: CEO EMMA WALMSLEY'S BOLD PRESCRIPTION FOR REVIVING GLAXOSMITHKLINE

EMMA WALMSLEY was just six weeks into her tenure as CEO of GlaxoSmithKline, the $38.9 billion British pharmaceutical firm, when "Glaxit"...

 
 
 

OXFORD REGENERATIVE MEDICINE SPINOUT BRINGS ON GLAXOSMITHKLINE DRUG HUNTER AS CSO

The University of Oxford's regenerative drug discovery spinout OxStem Limited has appointed Georg Terstappen as chief scientific officer,...

Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
 
 
 
Bio Roundup: An Alzheimer's Head-Scratcher, OUTBio, GSK & Gilead Shakeups  

BIO ROUNDUP: AN ALZHEIMER'S HEAD-SCRATCHER, OUTBIO, GSK & GILEAD SHAKEUPS  

The devil is in the details, and key clinical trial results made that abundantly clear this week. Eisai and partner Biogen released...

Here's the email 23andMe sent its customers after GSK bought a $300 million stake in the company

HERE'S THE EMAIL 23ANDME SENT ITS CUSTOMERS AFTER GSK BOUGHT A $300 MILLION STAKE IN THE COMPANY

Kimberly White/Getty 23andMe on Wednesday announced a partnership with pharma giant GlaxoSmithKline to develop new treatments for diseases...